RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...
Barchart on MSN
Cathie Wood is doubling down on Recursion Pharmaceuticals stock. Should you buy RXRX here?
Cathie Wood’s trades often read like a quiet manifesto – what she buys signals confidence, what she trims hints at fading ...
Recursion Pharmaceuticals (RXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Alec Stranahan from Bank of America Securities maintained a ...
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
In a report released today, Steven Mah from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The company’s shares closed today at $6.64. Mah covers the ...
Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...
Recursion Pharmaceuticals' stock experienced a 10.06% surge on Monday, indicating strong investor confidence in the company's innovations. The completion of BioHive-2 marks a pivotal moment for ...
Recursion Pharma is an AI-driven drug developer that boasts supercomputers designed to shorten drug development timelines and enhance successful outcomes. Many such companies have raised substantial ...
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback